SGLT2 Inhibitor Attenuates eGFR Slope in Type 2 Diabetes with UACR <30 mg/gCr

Related

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors raise genital but not urinary infection risk

  Clinical Pharmacology and Therapeutics · 4 Oct 2026

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026